For example, a study by Bose et al. published in 2013 showed that HER2 pathogenic activating mutations occur irrespectively of HER2 IHC status as they do not necessarily lead to protein overexpression, representing an alternative mechanism for activating the HER2 pathway in breast cancer (Bose et al., 2013). This evidence concerns the gene ERBB2 and breast carcinoma.